Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{b361e5ed3e844f00be3d42f4815392dd,
title = "Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19): a nationwide cohort study",
abstract = "OBJECTIVE: To investigate the association between recent statin exposure and risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 in Denmark.DESIGN AND SETTING: Observational cohort study using data from Danish nationwide registries.PARTICIPANTS: Patients diagnosed with COVID-19 from 22 February 2020 to 17 May 2020 were followed from date of diagnosis until outcome of interest, death or 17 May 2020.INTERVENTIONS: Use of statins, defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis.PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality, severe COVID-19 infection and the composite.RESULTS: The study population comprised 4842 patients with COVID-19 (median age 54 years (25th-75th percentile, 40-72), 47.1% men), of whom 843 (17.4%) redeemed a prescription of statins. Patients with statin exposure were more often men and had a greater prevalence of comorbidities. The median follow-up was 44 days. After adjustment for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30-day standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%); SAR difference, -0.4% (-1.9% to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41); 30-day SAR, 13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%); SAR difference, 1.9% (-0.7% to 4.5%)), and the composite outcome of all-cause mortality or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 1.23); 30-day SAR, 17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%); SAR difference, 0.6% (-1.6% to 2.9%)). The results were consistent across subgroups of age, sex and presumed indication for statin therapy. Among patients with statin exposure, there was no difference between statin drug or treatment intensity with respect to outcomes.CONCLUSIONS: Recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection.",
keywords = "cardiology, COVID-19, epidemiology",
author = "Butt, {Jawad Haider} and Gerds, {Thomas Alexander} and Morten Schou and Kristian Kragholm and Matthew Phelps and Eva Havers-Borgersen and Adelina Yafasova and Gislason, {Gunnar Hilmar} and Christian Torp-Pedersen and Lars K{\o}ber and Fosb{\o}l, {Emil Loldrup}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = dec,
day = "4",
doi = "10.1136/bmjopen-2020-044421",
language = "English",
volume = "10",
pages = "e044421",
journal = "BMJ Paediatrics Open ",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "12",

}

RIS

TY - JOUR

T1 - Association between statin use and outcomes in patients with coronavirus disease 2019 (COVID-19)

T2 - a nationwide cohort study

AU - Butt, Jawad Haider

AU - Gerds, Thomas Alexander

AU - Schou, Morten

AU - Kragholm, Kristian

AU - Phelps, Matthew

AU - Havers-Borgersen, Eva

AU - Yafasova, Adelina

AU - Gislason, Gunnar Hilmar

AU - Torp-Pedersen, Christian

AU - Køber, Lars

AU - Fosbøl, Emil Loldrup

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/12/4

Y1 - 2020/12/4

N2 - OBJECTIVE: To investigate the association between recent statin exposure and risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 in Denmark.DESIGN AND SETTING: Observational cohort study using data from Danish nationwide registries.PARTICIPANTS: Patients diagnosed with COVID-19 from 22 February 2020 to 17 May 2020 were followed from date of diagnosis until outcome of interest, death or 17 May 2020.INTERVENTIONS: Use of statins, defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis.PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality, severe COVID-19 infection and the composite.RESULTS: The study population comprised 4842 patients with COVID-19 (median age 54 years (25th-75th percentile, 40-72), 47.1% men), of whom 843 (17.4%) redeemed a prescription of statins. Patients with statin exposure were more often men and had a greater prevalence of comorbidities. The median follow-up was 44 days. After adjustment for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30-day standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%); SAR difference, -0.4% (-1.9% to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41); 30-day SAR, 13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%); SAR difference, 1.9% (-0.7% to 4.5%)), and the composite outcome of all-cause mortality or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 1.23); 30-day SAR, 17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%); SAR difference, 0.6% (-1.6% to 2.9%)). The results were consistent across subgroups of age, sex and presumed indication for statin therapy. Among patients with statin exposure, there was no difference between statin drug or treatment intensity with respect to outcomes.CONCLUSIONS: Recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection.

AB - OBJECTIVE: To investigate the association between recent statin exposure and risk of severe COVID-19 infection and all-cause mortality in patients with COVID-19 in Denmark.DESIGN AND SETTING: Observational cohort study using data from Danish nationwide registries.PARTICIPANTS: Patients diagnosed with COVID-19 from 22 February 2020 to 17 May 2020 were followed from date of diagnosis until outcome of interest, death or 17 May 2020.INTERVENTIONS: Use of statins, defined as a redeemed drug prescription in the 6 months prior to COVID-19 diagnosis.PRIMARY AND SECONDARY OUTCOME MEASURES: All-cause mortality, severe COVID-19 infection and the composite.RESULTS: The study population comprised 4842 patients with COVID-19 (median age 54 years (25th-75th percentile, 40-72), 47.1% men), of whom 843 (17.4%) redeemed a prescription of statins. Patients with statin exposure were more often men and had a greater prevalence of comorbidities. The median follow-up was 44 days. After adjustment for age, sex, ethnicity, socioeconomic status and comorbidities, statin exposure was not associated with a significantly different risk of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30-day standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%); SAR difference, -0.4% (-1.9% to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 0.95 to 1.41); 30-day SAR, 13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%); SAR difference, 1.9% (-0.7% to 4.5%)), and the composite outcome of all-cause mortality or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 1.23); 30-day SAR, 17.6% (16.4% to 18.8%) vs 18.2% (16.4% to 20.1%); SAR difference, 0.6% (-1.6% to 2.9%)). The results were consistent across subgroups of age, sex and presumed indication for statin therapy. Among patients with statin exposure, there was no difference between statin drug or treatment intensity with respect to outcomes.CONCLUSIONS: Recent statin exposure in patients with COVID-19 infection was not associated with an increased or decreased risk of all-cause mortality or severe infection.

KW - cardiology

KW - COVID-19

KW - epidemiology

UR - http://www.scopus.com/inward/record.url?scp=85097310673&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2020-044421

DO - 10.1136/bmjopen-2020-044421

M3 - Journal article

C2 - 33277291

VL - 10

SP - e044421

JO - BMJ Paediatrics Open

JF - BMJ Paediatrics Open

SN - 2044-6055

IS - 12

M1 - e044421

ER -

ID: 61404274